AbbVie set to receive $480 million from Takeda suit

Takeda had been asking for damages of just $295 million, according to Bloomberg Law.

The fight between AbbVie and Takeda began in 2019, when Takeda shut down one of its plants where it manufactured Lupron. The move cut Lupron supply to AbbVie, which the company says breached an agreement it had with Takeda. AbbVie first filed a lawsuit in November 2020.

In September 2021, Delaware Court’s Vice Chancellor Sam Glasscock III determined Takeda was liable for breaching the supply agreement.

In the new ruling, decided Tuesday, the judge found that AbbVie’s damages request and its methodology to calculate them is “reliable and appropriate.” However, Glasscock ordered some adjustments to the damages, meaning the exact amount to be paid is not yet known.

Takeda declined to comment. AbbVie did not respond to a request for comment.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source